Gastric Cancer Clinical Trials 2022
Browse 62 Gastric Cancer Medical Studies Across 243 Cities
7 Phase 3 Trial · 608 Gastric Cancer Clinics
What Are Gastric Cancer Clinical Trials?
Gastric cancer is one of the leading cancers in the world and is formed in the stomach lining. Stomach disease, diet, and age impact the risk of this cancer. The risk factors also include inherited conditions, H. pylori bacteria, and smoking. The symptoms include stomach pain or discomfort and indigestion.
Why Is Gastric Cancer Being Studied Through Clinical Trials?
Stomach cancer makes up about 1.5% of overall cancers diagnosed annually in the US. There are around 26,380 new gastric cancer and 11,090 fatalities annually. Gastric cancer is a significant health issue in the world. It is the 5th leading and 3rd deadliest cancer in the world, which is why finding effective treatments, preventive measures, and a cure through clinical trials and research is integral.
What Are The Types of Treatments Available For Gastric Cancer?
The treatment for stomach cancer is usually successful if cancer has been contained in the stomach and the prognosis for it is good. However, the diagnosis of gastric cancer is found once it has spread in most cases, making the cure more challenging. The treatment is based on the severity of cancer.
The major treatments for gastric cancer include:
-
Chemotherapy for stomach cancer
-
Immunotherapy for stomach cancer
-
Radiation therapy for stomach cancer
-
Surgery for stomach cancer
Targeted drug therapy for stomach cancer
What Are Some Recent Breakthrough Clinical Trials For Gastric Cancer?
2022: A clinical trial found the combination of pembrolizumab and chemotherapy as an effective treatment for gastroesophageal junction or gastric cancer. The standard treatment for gastric cancer is chemotherapy, but not all patients get beneficial results, which is why more treatment options are needed. The researchers tested the combination of these drugs among patients who can't handle triple chemotherapy and found optimistic results. The trial is now entering its third phase and is expected to alter the treatment options for gastric cancer.
2021: FDA granted approval to Opdivo (nivolumab) combined with different chemotherapy as an initial treatment for metastatic or advanced gastric cancer, esophageal adenocarcinoma, and gastroesophageal junction cancer. Nivolumab is the first immunotherapy approved by FDA as a first-line treatment for this cancer. This treatment is the first in over a decade with the potential to improve the survival rate of the patients getting first-time treatment.
Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Gastric Cancer Clinical Trials Research?
GI Cancers Alliance: This association is dedicated to spreading awareness and funding research for gastrointestinal cancers. It helps address the growing need for treatment, awareness, and screening of gastric cancer.
Gastric Cancer Foundation: This institution offers grants and funds to researchers working on projects and clinical trials related to under-funded diseases, particularly gastric cancer, to find a cure and effective preventive measures. The foundation launched a Gastric Cancer Registry to encourage and expand research and provide a practical and centralized resource for individuals with gastric cancer. The center also establishes partnerships and alliances to promote more investments in research and trials related to gastric cancer.
About The Author
Michael Gill - B. Sc.
First Published: October 5th, 2021
Last Reviewed: November 7th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.